HOPA 2018 | Treating GvHD: current challenges and newly approved drugs
Katie Gatwood
Graft versus host disease (GvHD) remains to be one of the leading causes of morbidity and mortality in patients who have undergone bone marrow transplant. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, briefly discusses the challenges with current treatment options for GvHD and gives an update on newly approved drugs that can be used to effectively treat patients. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Related videos
0:47
Patient monitoring following CAR T-cell therapy
Erik Aerts
1:06
The role of nurses in apheresis during CAR T-cell therapy
Erik Aerts
2:56
The future landscape of CAR T-cell therapy
Elaine Vickers
4:48
The quality control measures recommended within the JACIE model
Eoin McGrath
3:49
The limitations of immunotherapy with CAR T-cells
Elaine Vickers
